PharmaCyte Biotech PMCB Cash Flow Statement (2010-2026)

NASDAQ PMCB
$0.35 +0.00 (+0.81%)
As of: Oct 22, 2026 · 1:00 PM EDT
Reported Financials

PharmaCyte Biotech Quarterly Cash Flow Statement

Periods 65 quarters
Latest Jul 2026

PharmaCyte Biotech reported cash from operations of -$0.78M and free cash flow of -$0.78M for the quarter ended Jul 2026, up 60.8% year over year. This cash flow statement covers 65 quarters of results from Jul 2010 through Jul 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Jul2010 Oct2010 Jan2011 Apr2011 Jul2011 Oct2011 Jan2012 Apr2012 Jul2012 Oct2012 Jan2013 Apr2013 Jul2013 Oct2013 Jan2014 Apr2014 Jul2014 Oct2014 Jan2015 Apr2015 Jul2015 Oct2015 Jan2016 Apr2016 Jul2016 Oct2016 Jan2017 Apr2017 Jul2017 Oct2017 Jan2018 Apr2018 Jul2018 Oct2018 Jan2019 Apr2019 Jul2019 Oct2019 Jan2020 Apr2020 Jul2020 Oct2020 Jan2021 Apr2021 Jul2021 Oct2021 Jan2022 Apr2022 Jul2022 Oct2022 Jan2023 Apr2023 Jul2023 Oct2023 Jan2024 Apr2024 Jul2024 Oct2024 Jan2025 Apr2025 Jul2025 Oct2025 Jan2026 Apr2026 Jul2026
Operating Activities
Net Income
-0.98M-0.81M-1.42M-1.55M-1.88M-0.76M-0.13M-3.18M2.79M-0.62M1.35M23.42M-1.47M-3.05M11.75M-8.36M-7.42M0.75M-4.39M-5.08M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
Depreciation & Amortization (CF)Dep. & Amort.
Share-based CompensationStock Comp.
0.00M0.00M0.00M0.00M0.00M667.000.91M-0.91M0.67M0.22M0.12M-0.34M0.06M0.06M0.77M
Gains from Investment SecuritiesGains Investment
-0.53M-0.77M0.64M1.75M1.20M-4.27M-3.19M13.19M-4.83M6.05M1.73M-4.25M-5.55M
Other non-cash itemsOther Non-Cash
0.17M0.01M1.45M-4.08M-0.01M-0.91M-2.08M-1.83M-4.49M-1.98M0.06M10.47M-1.90M-3.40M
Change in Working Capital
Change in ReceivablesChange Receivables
Change in InventoryChange Inventory
Change in Account PayablesChange Payables
-0.01M-0.06M0.11M0.35M0.30M-0.58M-0.32M0.59M-0.59M0.36M-0.09M0.16M-0.21M0.14M-0.09M0.07M0.47M0.18M-0.84M0.12M
Change in Accured ExpensesChange Accured Exp.
-0.50M0.49M0.03M0.03M-0.08M-0.07M0.08M0.02M0.27M-0.25M0.14M-0.06M0.01M1.001.36M-1.01M-0.08M-0.54M0.08M-0.18M
Change in Other Operating AssetsOther Assets Change
-0.08M-0.07M-0.08M-0.07M0.23M-0.08M-0.07M-0.02M0.23M-0.03M-0.04M-0.02M0.25M-0.29M0.02M0.01M0.26M-0.34M0.32M0.12M
Change in Other Operating LiabilitiesOther Liabilities Change
1.45M
Other Working Capital ChangesOther WC Changes
0.08M0.07M0.08M0.07M-0.23M0.08M0.07M1.47M-0.23M0.03M0.04M0.02M-0.25M0.29M-0.02M-0.01M-0.26M0.34M-0.32M-0.12M
Cash from OperationsCash from Ops.
-1.39M-0.30M-1.19M-1.08M-1.88M-0.54M-0.29M0.34M-1.98M-0.18M-0.33M-0.37M-1.05M-0.51M-1.04M-1.99M-0.98M-0.79M-1.39M-0.78M
Investing Activities
Change in IntangiblesChange Intangibless
Acquisitions
Net of Acquisitions & DivestmentsNet Acquisitions
Purchase of InvestmentsInvestments Purchased
7.00M3.00M
Cash from Investing ActivitiesCash from Investing
-5.00M-7.00M-3.00M5.00M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
Long-Term Debt RepaymentsLT Debt Repayment
0.05M
Non-Current Debt
-0.05M
Net Debt Issuances and RepaymentsNet Debt Issuance
-0.05M
Change in Capital Stock
Common Stock IssuedStock Issued
87.36M880.0070.00
Shares Repurchased
2.09M3.39M3.78M4.31M26.46M0.16M0.40M1.17M0.74M1.40M0.23M0.17M0.40M
Net Shares Issued and RepurchasedNet Shares Issued
87.36M-2.09M-3.39M-3.78M-4.31M-26.46M-0.16M-0.40M-1.17M-0.74M-1.40M-0.23M-0.17M-0.40M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
35.00M-1.35M-6.64M-9.52M-9.43M-9.34M-3.72M-0.09M
Net Equity Issued and RepurchasedNet Equity Issued
87.36M-2.09M-3.39M-3.78M-4.31M8.54M-1.51M-7.04M-10.70M-10.17M-10.74M-3.95M-0.17M-0.40M-0.09M
Other financing activitiesOther financing
-2.26M
Cash from Financing ActivitiesCash from Financing
87.36M-0.05M-2.09M-3.39M-3.78M-4.31M6.28M0.75M-7.04M-10.70M-10.17M-10.74M-3.95M-0.17M6.21M0.54M-0.17M-0.08M
Additional items
Exchange Rate EffectFX Effect
0.00M-210.000.00M0.00M-720.000.00M-0.01M451.000.00M0.00M-438.00183.0061.000.00M617.00123.00-381.000.00M744.00-615.00
Change in Cash
85.98M-0.30M-1.24M-3.17M-5.27M-4.32M-4.60M6.62M-1.24M-12.21M-11.03M-17.54M-11.80M-4.46M-1.21M-1.99M2.23M4.76M-1.56M-0.86M
Ending Cash Balance
86.94M86.64M85.40M82.23M76.96M72.64M68.04M74.66M73.43M61.21M50.18M32.64M20.84M16.38M15.17M13.18M15.41M20.17M18.60M17.74M
Free Cash FlowFCF
-1.39M-0.30M-1.19M-1.08M-1.88M-0.54M-0.29M0.34M-1.98M-0.18M-0.33M-0.37M-1.05M-0.51M-1.04M-1.99M-0.98M-0.79M-1.39M-0.78M
Net Cash FlowNCF
85.98M-0.30M-1.24M-3.17M-5.26M-4.32M-4.60M6.62M-1.24M-12.22M-11.03M-17.55M-11.80M-4.46M-1.21M-1.99M2.23M4.76M-1.56M-0.86M
Interest Paid
42.00
Income Taxes PaidTaxes Paid
0.00M

PharmaCyte Biotech Cash Flow Statement API

Pull PharmaCyte Biotech's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=PMCB&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY